Nikhil Kamath water business idea: India's rapid growth in water-intensive sectors like agriculture, nuclear energy, pharmaceuticals, and d...

From a macro perspective, it is clearly a good time to be bullish. But as valuations remain high in parts of the market despite the recent ...

Global economic shocks from trade disruptions and geopolitical tensions are reshaping resilience, according to Raghuram Rajan. He stresses ...

Indian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...

Indian stocks are poised for a favorable period. Falling crude oil prices and a strengthening rupee offer support. Macroeconomic conditions...

Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...

Uzbekistan is inviting Indian drug companies to invest more. They are offering better subsidies and technology help. This aims to make Uzbe...

Indian pharma exports to the US face a subdued outlook this year. Policy uncertainties, falling generic prices, and regional conflicts are ...

There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...

If the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...

Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...

The U.S. is increasing pressure on Cuba, but unlike Venezuela, the island nation lacks a clear opposition leader or succession plan. Cuba's...

Leading analyst Devarsh Vakil suggests Indian markets offer compelling buying opportunities now, with valuations correcting to attractive l...

Global capital is shifting towards electronics and AI in Asia. India's foreign direct investment slowdown is not a major concern. Asia's ex...

Market expert Dipan Mehta finds India's current earnings season strong. He notes that future quarters will test corporate India due to pote...

As far as India is concerned, the biggest pain point from the US-Iran war in the Gulf region has been the spike in the prices of not only o...

Indian pharmaceutical exports reached over $31 billion in FY26. March saw a significant 23% drop, primarily due to a slowdown in the United...